Get to know the new venture capital funds and venture capital is that have emerged in the month of December and all the related information: size, commitments, objective, promoters,...
Find out about the new venture capital and venture capital funds that have emerged in the month of December and all related information: size, commitments, objective, promoters,...
The background Charme Capital Partners finalises the final closing of its new venture capital vehicle in Europe, which will arrive by the end of the year with an amount close to €650M. This amount far exceeds the initial target of €250m, with commitments of €400m.
The objective of this new fund is to invest in mid-sized European companies, with Spain, Italy and the UK as priority targets, with a valuation of €100M to €500M and strong growth potential. One of the investees of this new investment vehicle is Igenomix, a world leader in the development of genetic fertility tests. Its limited partners include family offices and industrial investors.
Aina Hospitalitya management company specialising in the hotel sector and promoted by the large asset management group Edmund de RothschildThe company plans to invest €600m with its second fund, which will target four-star superior and five-star hotels. The two entities have set up a joint venture to promote investment funds in the hotel sector every three years.
Fundraising will start in September and run for a year and a half, with a first closing window in March 2018. It aims to reach €300M and double its capacity to €600M with leverage. While in its first fund, Aina I, the minimum entry investment was €1M, for Aina II there is no set ticket, although it is expected to be higher. The return of Aina II will be close to 12% per annum and will extend its scope to 35 European cities, including countries outside the eurozone such as the UK, Switzerland and Scandinavia.
The venture capital manager Mediterrania Capital Partners (MCP) is now ready to launch its third fund specialising in small and medium-sized companies in the Maghreb. Unlike the two previous vehicles, Mediterrania Capital III (MC III) will also invest in Egypt, Senegal, Cameroon and Côte d'Ivoire, in addition to Morocco, Tunisia and Algeria. The new fund already has €103m committed, slightly more than the €100m initially planned. Mediterrania expects to complete this vehicle by December 2018 with €250M. MC III will carry out eight to twelve transactions of €10M to €30M, in key sectors in North Africa and Sub-Saharan Africa, such as healthcare, consumer goods, finance, education, transport and logistics.
The Valencian firm Decenes Mecenes (DCN) has registered with the CNMV the venture capital fund Dosbio50 Life Science & Health Care Venture Capital Investments, which plans to manage more than €40M to invest in seed and/or development capital projects in the biomedicine sector. Dosbio50 will be managed by its sole administrator, the DCN management company, which received in April the relevant authorization from the CNMV and is chaired by Lucas Martínez Clar and owned 5.49% by the Valencian investment firm Realiza Business Angels.
Throughout its ten years of existence, Realiza Business Angels has made a total of 17 investments in the Life Science sector (health sciences) with Artax Biopharma, Imegen, BioncoTech, Universal Diagnostics and the aforementioned Dosbio50; digital technology with Jugo, 50Tresdigital, Encom, Beroomers, Nextail and Weplan; as well as Soluble Film Packaking and Consultia Travel. It has also divested SFP, Corporate Channels, Geothermal Energy and Photomiracle.
The Mondragon Corporation has launched "Mondragón Fondo de Promoción F.C.R.", already registered at the CNMV, operational and managed by the venture capital firm Major Key. This is a new investment vehicle for spin-outs that aims to support the technology transfer of innovative technology-based projects in the industrial, health and energy sectors, mainly from the Corporation itself.
The fund, closed with commitments of €15 million, also has the participation of FOND-ICO Global FCR, and the venture capital companies of the Basque and Navarre Governments, as well as the Provincial Council of Gipuzkoa. The investment vehicle will invest over the next 6 years in 30 companies with less than two years of life, remaining between 4 and 5 years in each of the investees and allocating up to €500,000 to each of them.
Genesis Venturesa new investment fund based in Barcelona and made up of several family offices, will invest in very early-stage research and business projects in the biomedical field: therapeutics, diagnostics, medical devices, digital health, among others. Its objective is to help entrepreneurs to achieve the necessary value of their research in order to subsequently attract the first round of investment from corporate funds or venture capital (Series A). The new fund will have a size of around €610,000 and expects to do a total of eight deals by October 2019.
Eneko Knörr, supported by a team of blockchain and cryptocurrency experts from Silicon Valley, Singapore and Spain, has launched PheidonThe fund will start operating in 2018 and is still awaiting approval from the CNMV (Spanish Securities and Exchange Commission). The fund aims to facilitate investment in Bitcoin since, according to Knörr, "I have been seeing great interest in Spain in investing in Bitcoin for some time, but it is not easy: small savers find the process very complicated, and large fortunes do not have any funds from which to invest".